- Nachrichtendetail
-
03.04.2024 17:43:56 - Medartis launches senior convertible bond -2-
DJ Medartis launches senior convertible bond offering in a private placement of approximately CHF 115 million due 2031
===
Medartis Holding AG / Key word(s): Financing/Issue of Debt
Medartis launches senior convertible bond offering in a private placement of approximately CHF 115 million due 2031
03-Apr-2024 / 17:43 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this
announcement.
Basel, 3 April 2024: Medartis Holding AG (SIX: MED, the "Company" or "Medartis"), a specialized orthopaedic company for
head and extremity surgery, today announces the launch of a private placement offering (the "Offering") of approx. CHF
115 million senior unsecured guaranteed convertible bonds due 2031 (the "Bonds"). The Bonds will be issued via the
Company's directly wholly-owned subsidiary, Medartis International Finance SAS (the "Issuer"), guaranteed by the
Company and convertible into newly issued and/or existing registered shares of the Company. Advanced subscription
rights for existing shareholders are excluded in the Offering.
Medartis intends to use the net proceeds of the Bonds for general financing purposes, including acquisitions in its
core business. The Bonds will be issued with a denomination of CHF 200,000 per bond at 100% of their principal amount.
The Bonds are expected to carry a coupon of between 2.75% and 3.25% per annum, payable semi-annually in arrear, and
will have a conversion price set at a premium of between 25% and 30% over the reference share price. The reference
share price is expected to be equal to the placement price per Medartis share determined in the Concurrent Delta
Placement (as further described below). Unless previously converted, redeemed or, repurchased and cancelled, the Bonds
will be redeemed at 100% of their principal amount on the stated maturity date, which is expected to be on 11 April
2031. Advanced subscription rights for existing shareholders are excluded in the Offering.
Medartis will be entitled to redeem the Bonds at their principal amount plus accrued interest in accordance with the
terms and conditions of the Bonds at any time (i) on or after 2 May 2029, if the price of a Medartis share is equal to
or exceeds 130% of the then prevailing conversion price over a certain period or (ii) if less than 15% of the aggregate
principal amount of the Bonds remain outstanding. Holders of the Bonds will be entitled to request an early redemption
of their Bonds on the fifth anniversary of their issue at their principal amount plus accrued interest.
The Offering will be conducted as a private placement in and outside of Switzerland. The Bonds will be offered by way
of an accelerated bookbuilding process to institutional investors outside the US (in reliance on Regulation S under the
US Securities Act of 1933), as amended, and in compliance with the laws and regulations applicable in every country
where the Offering takes place.
The Bonds are expected to price before the market opens on 4 April 2024, and the settlement (the "Settlement Date") is
expected to be on or around 11 April 2024. Application for the admission to trading of the Bonds on the Open Market of
the Frankfurt Stock Exchange ('Freiverkehr') is expected to be made no later than three months after the Settlement
Date. The Bonds will not be admitted to trading or listing on the SIX Swiss Exchange, where the underlying Medartis
shares are listed and traded, or any other trading venue in Switzerland.
The Company, the Issuer as well as the Company's main shareholder Dr. h.c. Thomas Straumann (currently holding 45.5% of
the outstanding shares) have agreed to a 180-day lock-up following the Settlement Date, subject to certain customary
exceptions and waiver by the Joint Bookrunners (as defined below).
BofA Securities Europe SA is acting as Sole Global Coordinator and, together with the Zürcher Kantonalbank (ZKB), as
Joint Bookrunners for the Offering. Concurrently with the Offering, the Joint Bookrunners have been mandated by
Medartis to facilitate hedging the market risk for certain subscribers of the Bonds and to organize a simultaneous
placement of existing shares of the Company (the "Concurrent Delta Placement"). The Company will not receive any
proceeds from the placement of these shares.
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss Exchange: MED / ISIN CH0386200239) is one
of the world's leading manufacturers and suppliers of medical devices for the surgical fixation of bone fractures in
the upper and lower extremities and the craniomaxillofacial region. Medartis employs more than 860 people in 13
locations and its products are sold in more than 50 countries worldwide. Medartis is committed to providing surgeons
and surgical staff with the most innovative titanium implants and instruments, as well as world-class service. For more
information, please visit www.medartis.com.
Disclaimer
THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF MEDARTIS HOLDING AG (THE
"COMPANY") AND MEDARTIS INTERNAT. FINANCE SAS (THE "ISSUER").
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR
COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR
ITS ACCURACY, FAIRNESS OR COMPLETENESS.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SHARES, CONVERTIBLE BONDS
OR OTHER SECURITIES IN THE COMPANY OR THE ISSUER (COLLECTIVELY, THE "SECURITIES") TO ANY PERSON IN THE UNITED STATES,
AUSTRALIA, CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS
UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE
RESTRICTED OR PROHIBITED BY LAW.
THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION
OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT
OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE
TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED. IN PARTICULAR, THE SECURITIES OF THE COMPANY
AND THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE
REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO
CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR
TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER THE
SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS
DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.
IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT
AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE
PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) ("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS
DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS
FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS
AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE
LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND
IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.
THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD-LOOKING STATEMENTS". THESE
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS "BELIEVES",
"ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS", "INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE,
THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS,
FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY
FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER'S OR THE COMPANY'S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE
SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP'S
BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING
STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR
RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING
STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.
THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN THE MEANING OF THE ARTICLES 35 ET SEQQ.
AND 69 OF THE SWISS FEDERAL ACT ON FINANCIAL SERVICES ("FINSA") OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE
===
(MORE TO FOLLOW) Dow Jones Newswires
April 03, 2024 11:43 ET (15:43 GMT)
===
APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. THE SECURITIES MAY NOT BE PUBLICLY OFFERED, DIRECTLY OR INDIRECTLY, IN
SWITZERLAND WITHIN THE MEANING OF FINSA AND NO APPLICATION HAS OR WILL BE MADE TO ADMIT THE SECURITIES TO TRADING ON
ANY TRADING VENUE (EXCHANGE OR MULTILATERAL TRADING FACILITY) IN SWITZERLAND. THE OFFERING OF SECURITIES IN SWITZERLAND
IS EXEMPT FROM THE REQUIREMENT TO PREPARE AND PUBLISH A PROSPECTUS. NO OFFERING OR MARKETING MATERIAL RELATING TO THE
SECURITIES MAY BE PUBLICLY DISTRIBUTED OR OTHERWISE MADE PUBLICLY AVAILABLE IN SWITZERLAND.
THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE. THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND
THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE
CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR
PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING,
THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.
IN CONNECTION WITH THE OFFERING OF THE SECURITIES, THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A
PORTION OF THE SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN, PURCHASE, SELL,
OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED
INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF THEIR
AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH
INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE,
HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT
OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.
NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY
RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE
TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED
FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED
COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELEC- TRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR
FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION
THEREWITH.
NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH,
ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
Your contact:
Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel
Corporate Communications
Investor contact: investor.relations@medartis.com
Media contact: corporate.communication@medartis.com
+41 61 633 37 36
Hochbergerstrasse 60E
4057 Basel
Switzerland
End of Announcement EQS News Service
===
1872765 03-Apr-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1872765&application_name=news
END) Dow Jones Newswires
April 03, 2024 11:43 ET (15:43 GMT)
===
Medartis Holding AG / Key word(s): Financing/Issue of Debt
Medartis launches senior convertible bond offering in a private placement of approximately CHF 115 million due 2031
03-Apr-2024 / 17:43 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this
announcement.
Basel, 3 April 2024: Medartis Holding AG (SIX: MED, the "Company" or "Medartis"), a specialized orthopaedic company for
head and extremity surgery, today announces the launch of a private placement offering (the "Offering") of approx. CHF
115 million senior unsecured guaranteed convertible bonds due 2031 (the "Bonds"). The Bonds will be issued via the
Company's directly wholly-owned subsidiary, Medartis International Finance SAS (the "Issuer"), guaranteed by the
Company and convertible into newly issued and/or existing registered shares of the Company. Advanced subscription
rights for existing shareholders are excluded in the Offering.
Medartis intends to use the net proceeds of the Bonds for general financing purposes, including acquisitions in its
core business. The Bonds will be issued with a denomination of CHF 200,000 per bond at 100% of their principal amount.
The Bonds are expected to carry a coupon of between 2.75% and 3.25% per annum, payable semi-annually in arrear, and
will have a conversion price set at a premium of between 25% and 30% over the reference share price. The reference
share price is expected to be equal to the placement price per Medartis share determined in the Concurrent Delta
Placement (as further described below). Unless previously converted, redeemed or, repurchased and cancelled, the Bonds
will be redeemed at 100% of their principal amount on the stated maturity date, which is expected to be on 11 April
2031. Advanced subscription rights for existing shareholders are excluded in the Offering.
Medartis will be entitled to redeem the Bonds at their principal amount plus accrued interest in accordance with the
terms and conditions of the Bonds at any time (i) on or after 2 May 2029, if the price of a Medartis share is equal to
or exceeds 130% of the then prevailing conversion price over a certain period or (ii) if less than 15% of the aggregate
principal amount of the Bonds remain outstanding. Holders of the Bonds will be entitled to request an early redemption
of their Bonds on the fifth anniversary of their issue at their principal amount plus accrued interest.
The Offering will be conducted as a private placement in and outside of Switzerland. The Bonds will be offered by way
of an accelerated bookbuilding process to institutional investors outside the US (in reliance on Regulation S under the
US Securities Act of 1933), as amended, and in compliance with the laws and regulations applicable in every country
where the Offering takes place.
The Bonds are expected to price before the market opens on 4 April 2024, and the settlement (the "Settlement Date") is
expected to be on or around 11 April 2024. Application for the admission to trading of the Bonds on the Open Market of
the Frankfurt Stock Exchange ('Freiverkehr') is expected to be made no later than three months after the Settlement
Date. The Bonds will not be admitted to trading or listing on the SIX Swiss Exchange, where the underlying Medartis
shares are listed and traded, or any other trading venue in Switzerland.
The Company, the Issuer as well as the Company's main shareholder Dr. h.c. Thomas Straumann (currently holding 45.5% of
the outstanding shares) have agreed to a 180-day lock-up following the Settlement Date, subject to certain customary
exceptions and waiver by the Joint Bookrunners (as defined below).
BofA Securities Europe SA is acting as Sole Global Coordinator and, together with the Zürcher Kantonalbank (ZKB), as
Joint Bookrunners for the Offering. Concurrently with the Offering, the Joint Bookrunners have been mandated by
Medartis to facilitate hedging the market risk for certain subscribers of the Bonds and to organize a simultaneous
placement of existing shares of the Company (the "Concurrent Delta Placement"). The Company will not receive any
proceeds from the placement of these shares.
About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis (SIX Swiss Exchange: MED / ISIN CH0386200239) is one
of the world's leading manufacturers and suppliers of medical devices for the surgical fixation of bone fractures in
the upper and lower extremities and the craniomaxillofacial region. Medartis employs more than 860 people in 13
locations and its products are sold in more than 50 countries worldwide. Medartis is committed to providing surgeons
and surgical staff with the most innovative titanium implants and instruments, as well as world-class service. For more
information, please visit www.medartis.com.
Disclaimer
THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF MEDARTIS HOLDING AG (THE
"COMPANY") AND MEDARTIS INTERNAT. FINANCE SAS (THE "ISSUER").
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR
COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR
ITS ACCURACY, FAIRNESS OR COMPLETENESS.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SHARES, CONVERTIBLE BONDS
OR OTHER SECURITIES IN THE COMPANY OR THE ISSUER (COLLECTIVELY, THE "SECURITIES") TO ANY PERSON IN THE UNITED STATES,
AUSTRALIA, CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS
UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE
RESTRICTED OR PROHIBITED BY LAW.
THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION
OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT
OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE
TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED. IN PARTICULAR, THE SECURITIES OF THE COMPANY
AND THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE
REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO
CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR
TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER THE
SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS
DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.
IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT
AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE
PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) ("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS
DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS
FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS
AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE
LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND
IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.
THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD-LOOKING STATEMENTS". THESE
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS "BELIEVES",
"ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS", "INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE,
THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS,
FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY
FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER'S OR THE COMPANY'S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE
SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP'S
BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING
STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR
RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING
STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.
THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN THE MEANING OF THE ARTICLES 35 ET SEQQ.
AND 69 OF THE SWISS FEDERAL ACT ON FINANCIAL SERVICES ("FINSA") OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE
===
(MORE TO FOLLOW) Dow Jones Newswires
April 03, 2024 11:43 ET (15:43 GMT)
===
APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. THE SECURITIES MAY NOT BE PUBLICLY OFFERED, DIRECTLY OR INDIRECTLY, IN
SWITZERLAND WITHIN THE MEANING OF FINSA AND NO APPLICATION HAS OR WILL BE MADE TO ADMIT THE SECURITIES TO TRADING ON
ANY TRADING VENUE (EXCHANGE OR MULTILATERAL TRADING FACILITY) IN SWITZERLAND. THE OFFERING OF SECURITIES IN SWITZERLAND
IS EXEMPT FROM THE REQUIREMENT TO PREPARE AND PUBLISH A PROSPECTUS. NO OFFERING OR MARKETING MATERIAL RELATING TO THE
SECURITIES MAY BE PUBLICLY DISTRIBUTED OR OTHERWISE MADE PUBLICLY AVAILABLE IN SWITZERLAND.
THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE. THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND
THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE
CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR
PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING,
THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.
IN CONNECTION WITH THE OFFERING OF THE SECURITIES, THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A
PORTION OF THE SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN, PURCHASE, SELL,
OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED
INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF THEIR
AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH
INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE,
HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT
OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.
NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY
RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE
TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED
FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED
COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELEC- TRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR
FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION
THEREWITH.
NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH,
ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
Your contact:
Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel
Corporate Communications
Investor contact: investor.relations@medartis.com
Media contact: corporate.communication@medartis.com
+41 61 633 37 36
News Source: Medartis Holding AG End of Inside Information Language: English Company: Medartis Holding AG
Hochbergerstrasse 60E
4057 Basel
Switzerland
Phone: +41 61 633 34 34 Fax: +41 61 633 34 00 E-mail: info@medartis.com Internet: www.medartis.com ISIN: CH0386200239 Valor: 38620023 Listed: SIX Swiss Exchange EQS News ID: 1872765
End of Announcement EQS News Service
===
1872765 03-Apr-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1872765&application_name=news
END) Dow Jones Newswires
April 03, 2024 11:43 ET (15:43 GMT)
